Author

André Korrat

Observed names: A. Korrat, Andre Korrat, Korrat, A

OpenAlex ID: A5076633419

Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.

2007 · Heinz-Herbert Fiebig, Julia Schüler, et al. · PubMed · 39

Gene signature-based prediction of tumor response to cyclophosphamide.

2007 · André Korrat, Thomas Greiner, et al. · PubMed · 13

Predictive gene signatures for bevacizumab and cetuximab as well as cytotoxic agents

2011 · Heinz-Herbert Fiebig, Vincent Vuaroqueaux, et al. · International Journal of Clinical Pharmacology and Therapeutics · 7

Determination of a 35 gene signature predictive for the effectiveness of Bevacizumab

2007 · Heinz H. Fiebig, Julia Schüler, et al. · Molecular Cancer Therapeutics · 3

Abstract 2598: Evaluation of antitumor efficacy of Trabectedin in patient derived tumor xenografts in vitro and in vivo, and determination of a predictive gene signature

2010 · Armin Maier, Andre Korrat, et al. · Cancer Research · 1

Abstract B271: In vitro profiling of traditional tubulin targeting and new antimitotic compounds by using a 40 cancer cell line panel in combination with Compare Analysis

2009 · Gerhard Kelter, Thomas Metz, et al. · Molecular Cancer Therapeutics · 1

628 Stem cell marker expression profile in colon cancer xenografts and their corresponding cell lines

2010 · M. Schneider, A. Maier, et al. · European Journal of Cancer Supplements

Abstract C120: Testing a gene expression based signature predicting Cetuximab sensitivity in wild type KRAS tumors expressing EGFR

2009 · Vincent Vuaroqueaux, Andre Korrat, et al. · Molecular Cancer Therapeutics

79 POSTER Development of a gene signature predicting response to Cetuximab in human tumor xenograft models

2008 · H. Fiebig, J.B. Schüler, et al. · European Journal of Cancer Supplements

185 POSTER Chlamydocin, a HDAC inhibitor identified by Compare analyses in a cellular screen

2008 · H.H. Fiebig, T. Metz, et al. · European Journal of Cancer Supplements

A customized 1600 gene expression array for the prediction of tumor response against targeted and cytotoxic drugs

2008 · A. Korrat, T. Metz, et al. · Journal of Clinical Oncology

Do gene signatures predict effectiveness of bevacizumab and cetuximab?

2008 · H. H. Fiebig, J. Schüler, et al. · Journal of Clinical Oncology

Antitumor activity of Bevacizumab in a panel of 99 patient derived tumor models in vivo in relation to proteomic biomarker profiles

2007 · Heinz H. Fiebig, Thomas Metz, et al. · Molecular Cancer Therapeutics

Oncotest customized 1600 gene expression array for the prediction of tumor response against targeted and cytotoxic drugs

2007 · André Korrat, Heinz H. Fiebig, et al. · Molecular Cancer Therapeutics

In vitro profiling of 5 HDAC inhibitors in 59 human tumor cell lines: Selective activity in AML, NHL and myelomas: Development of a predictive gene signature

2007 · Gerhard Kelter, Thomas Metz, et al. · Molecular Cancer Therapeutics

Chemosensitivity of patient derived human tumor xenograft models against 5FU, Capecitabin, CPT-11 and Oxaliplatin

2007 · Heinz H. Fiebig, Thomas U. Greiner, et al. · Cancer Research

Works count: 17

Citation count: 64

H-index: 3

I10-index: 2